Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial resultsHolger W. Auner, Gordon Cook, Gareth J. Morgan et al.|Blood Cancer Journal|2022Cited by 15
CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trialRob Coleman, Sarah Brown, Janet E. Brown et al.|Trials|2020Cited by 15
A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial resultsMatthew Winter, Janet E. Brown, Rob Coleman et al.|Journal of bone oncology|2022Cited by 10
Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five StudyKwee Yong, Roger G. Owen, Samantha Hinsley et al.|Blood|2018Cited by 6
CTIM-14. PELAREOREP AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) WITH STANDARD CHEMORADIOTHERAPY/ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA MULTIFORME (GBM) PATIENTS: REOGLIO PHASE I TRIAL RESULTSJessica Kendall, Susan Short, Anthony J. Chalmers et al.|Neuro-Oncology|2020Cited by 3